Your browser doesn't support javascript.
loading
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
Okuda, Darin T; Siva, Aksel; Kantarci, Orhun; Inglese, Matilde; Katz, Ilana; Tutuncu, Melih; Keegan, B Mark; Donlon, Stacy; Hua, Le H; Vidal-Jordana, Angela; Montalban, Xavier; Rovira, Alex; Tintoré, Mar; Amato, Maria Pia; Brochet, Bruno; de Seze, Jérôme; Brassat, David; Vermersch, Patrick; De Stefano, Nicola; Sormani, Maria Pia; Pelletier, Daniel; Lebrun, Christine.
Affiliation
  • Okuda DT; University of Texas Southwestern Medical Center, Department of Neurology & Neurotherapeutics, Clinical Center for Multiple Sclerosis, Dallas, Texas, United States of America.
  • Siva A; University of Istanbul, Department of Neurology, Cerrahpasa School of Medicine, Istanbul, Turkey.
  • Kantarci O; Mayo Clinic College of Medicine, Department of Neurology, Rochester, Minnesota, United States of America.
  • Inglese M; Mt. Sinai School of Medicine, Department of Neurology, Radiology and Neuroscience, New York, New York, United States of America.
  • Katz I; Mt. Sinai School of Medicine, Department of Neurology, Radiology and Neuroscience, New York, New York, United States of America.
  • Tutuncu M; University of Istanbul, Department of Neurology, Cerrahpasa School of Medicine, Istanbul, Turkey.
  • Keegan BM; Mayo Clinic College of Medicine, Department of Neurology, Rochester, Minnesota, United States of America.
  • Donlon S; Barrow Neurological Institute, Department of Neurology, Phoenix, Arizona, United States of America.
  • Hua le H; Cleveland Clinic Lou Ruvo Center for Brain Health, Department of Neurology, Las Vegas, Nevada, United States of America.
  • Vidal-Jordana A; MS Center of Catalunya Cemcat and Magnetic Resonance Unit, Vall d'Hebron Hospital, Barcelona, Spain.
  • Montalban X; MS Center of Catalunya Cemcat and Magnetic Resonance Unit, Vall d'Hebron Hospital, Barcelona, Spain.
  • Rovira A; MS Center of Catalunya Cemcat and Magnetic Resonance Unit, Vall d'Hebron Hospital, Barcelona, Spain.
  • Tintoré M; MS Center of Catalunya Cemcat and Magnetic Resonance Unit, Vall d'Hebron Hospital, Barcelona, Spain.
  • Amato MP; University of Florence, Department of Neurology, Florence, Italy.
  • Brochet B; Centre Hospitalo Universitaire Bordeaux, Bordeaux, France.
  • de Seze J; Centre Hospitalo Universitaire Strasbourg, Strasbourg, France.
  • Brassat D; Centre Hospitalo Universitaire Purpan, Toulouse, France.
  • Vermersch P; Centre Hospitalo Universitaire Salengro, Lille, France.
  • De Stefano N; University of Siena, Department of Medicine, Surgery & Neuroscience, Siena, Italy.
  • Sormani MP; University of Genoa, Department of Health Sciences (DISSAL), Genoa, Italy.
  • Pelletier D; Yale University, Departments of Neurology and Diagnostic Radiology, New Haven, Connecticut, United States of America.
  • Lebrun C; Hôpital Pasteur, Service de Neurologie, Nice, France.
PLoS One ; 9(3): e90509, 2014.
Article in En | MEDLINE | ID: mdl-24598783
OBJECTIVE: To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. METHODS: Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. RESULTS: Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=<0.001] were identified as significant predictors for the development of a first clinical event. INTERPRETATION: These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age <37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2014 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2014 Type: Article Affiliation country: United States